Log in

NASDAQ:APVOAptevo Therapeutics Stock Price, Forecast & News

$5.83
-0.12 (-2.02 %)
(As of 06/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.76
Now: $5.83
$6.05
50-Day Range
$3.66
MA: $5.32
$7.65
52-Week Range
$2.94
Now: $5.83
$14.56
Volume27,507 shs
Average Volume95,307 shs
Market Capitalization$18.85 million
P/E RatioN/A
Dividend YieldN/A
Beta2.71
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its investigational stage product candidates comprise APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome; APVO210, an anti-inflammatory molecule that is in pre-clinical development stage for the treatment of autoimmune and inflammatory diseases; ALG.APV-527, a bispecific antibody to target T cells; ROR1 Bispecific, a proof-of-concept bispecific candidate that is in preclinical development; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Read More
Aptevo Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APVO
CUSIPN/A
Phone206-838-0500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.42 million
Book Value$3.66 per share

Profitability

Net Income$-40,450,000.00
Net Margins-102.54%

Miscellaneous

Employees118
Market Cap$18.85 million
Next Earnings Date8/14/2020 (Estimated)
OptionableOptionable

Receive APVO News and Ratings via Email

Sign-up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.

Aptevo Therapeutics (NASDAQ:APVO) Frequently Asked Questions

How has Aptevo Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Aptevo Therapeutics' stock was trading at $0.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, APVO stock has increased by 1,288.1% and is now trading at $5.83. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aptevo Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aptevo Therapeutics.

When is Aptevo Therapeutics' next earnings date?

Aptevo Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Aptevo Therapeutics.

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc (NASDAQ:APVO) issued its earnings results on Wednesday, May, 13th. The biotechnology company reported ($2.84) EPS for the quarter, missing analysts' consensus estimates of ($2.35) by $0.49. Aptevo Therapeutics had a negative return on equity of 224.05% and a negative net margin of 102.54%. View Aptevo Therapeutics' earnings history.

What price target have analysts set for APVO?

1 equities research analysts have issued 1-year price targets for Aptevo Therapeutics' shares. Their forecasts range from $3.00 to $18.50. On average, they anticipate Aptevo Therapeutics' stock price to reach $10.75 in the next year. This suggests a possible upside of 84.4% from the stock's current price. View analysts' price targets for Aptevo Therapeutics.

Has Aptevo Therapeutics been receiving favorable news coverage?

News headlines about APVO stock have been trending negative on Friday, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aptevo Therapeutics earned a news sentiment score of -2.7 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutAptevo Therapeutics.

Are investors shorting Aptevo Therapeutics?

Aptevo Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 53,000 shares, a decline of 8.5% from the April 30th total of 57,900 shares. Based on an average trading volume of 120,500 shares, the days-to-cover ratio is currently 0.4 days. Approximately 1.8% of the company's stock are sold short. View Aptevo Therapeutics' Current Options Chain.

Who are some of Aptevo Therapeutics' key competitors?

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Amarin (AMRN), Axsome Therapeutics (AXSM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and Netflix (NFLX).

Who are Aptevo Therapeutics' key executives?

Aptevo Therapeutics' management team includes the following people:
  • Mr. Marvin L. White, Pres, CEO & Director (Age 57)
  • Mr. Jeffrey G. Lamothe, Sr. VP, CFO & Treasurer (Age 53)
  • Dr. Scott C. Stromatt, Sr. VP of Clinical Devel. & Medical Affairs and Chief Medical Officer (Age 61)
  • Mr. Randy Joe Maddux, Sr. VP of Operations & Chief Manufacturing Officer (Age 58)
  • Dr. Jane A. Gross, Sr. VP & Chief Scientific Officer (Age 62)

What is Aptevo Therapeutics' stock symbol?

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

Who are Aptevo Therapeutics' major shareholders?

Aptevo Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (0.68%) and UBS Group AG (0.36%). Company insiders that own Aptevo Therapeutics stock include Barbara Lopez Kunz, Daniel Abdun-Nabi, Fuad El-Hibri, Grady Grant III, Marvin L White, Randy Joe Maddux and Zsolt Harsanyi. View institutional ownership trends for Aptevo Therapeutics.

Which major investors are selling Aptevo Therapeutics stock?

APVO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., and UBS Group AG. View insider buying and selling activity for Aptevo Therapeutics.

How do I buy shares of Aptevo Therapeutics?

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aptevo Therapeutics' stock price today?

One share of APVO stock can currently be purchased for approximately $5.83.

How big of a company is Aptevo Therapeutics?

Aptevo Therapeutics has a market capitalization of $18.85 million and generates $32.42 million in revenue each year. The biotechnology company earns $-40,450,000.00 in net income (profit) each year or ($15.27) on an earnings per share basis. Aptevo Therapeutics employs 118 workers across the globe.

What is Aptevo Therapeutics' official website?

The official website for Aptevo Therapeutics is www.aptevotherapeutics.com.

How can I contact Aptevo Therapeutics?

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.